11/19/2018

Cefpodoxime Oral Suspension

Products Affected - Description

- Cefpodoxime oral suspension, Sandoz, 100 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6169-46
- Cefpodoxime oral suspension, Sun Pharma, 50 mg/5 mL, 100 mL bottle, 1 count, NDC 63304-0965-04
- Cefpodoxime oral suspension, Sun Pharma, 50 mg/5 mL, 50 mL bottle, 1 count, NDC 63304-0965-03

Reason for the Shortage

- Aurobindo has discontinued cefpodoxime oral suspension.
- Sandoz has discontinued cefpodoxime oral suspension.
- Sun Pharma has discontinued cefpodoxime oral suspension.
- Northstar only provides product to McKesson customers.
- Rising has product available.

Available Products

- Cefpodoxime oral suspension, Northstar LLC, 100 mg/5 mL, 50 mL bottle, 1 count, NDC 16714-0403-01
- Cefpodoxime oral suspension, Northstar LLC, 50 mg/5 mL, 100 mL bottle, 1 count, NDC 16714-0402-02
- Cefpodoxime oral suspension, Northstar LLC, 50 mg/5 mL, 50 mL bottle, 1 count, NDC 16714-0402-01
- Cefpodoxime oral suspension, Rising Pharmaceuticals, 100 mg/5 mL, 100 mL bottle, 1 count, NDC 64980-0403-10
- Cefpodoxime oral suspension, Rising Pharmaceuticals, 100 mg/5 mL, 50 mL bottle, 1 count, NDC 64980-0403-50

Estimated Resupply Dates

- All marketed presentations are available.

Updated

Updated November 19, 2018 by Leslie Jensen, PharmD, Drug Information Specialist. Created April 6, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.